Review Summarizes Clinical Research on Novonesis’ Probiotic BB-12

A review published in Frontiers in Microbiology consolidates decades of research on a probiotic marketed by Novonesis as BB-12 (Bifidobacterium animalis subsp. Lactis), covering mechanisms of action, clinical efficacy, and relevance across life stages.

Evidence can be fragmented and difficult to navigate, and the review serves as a single, accessible source to evaluate, the company noted.

“It’s very exciting that we’re able to share this with our customers now,” said Linda Neckmar, senior vice president of human health at Novonesis. “We’ve known about the many benefits of the BB-12 strain for a long time, but this comprehensive review is a powerful tool for anyone working with it. It helps our partners communicate on health benefits with confidence, backed by science.”

The review includes information on BB-12’s:

• Survival in the gastrointestinal tract
• Bile salt tolerance
• Metabolic activity
• Adherence to intestinal epithelial cells
• Immune modulation
• Impact on gut microbiota and short-chain fatty acid production
• Clinical efficacy on constipation and infant colic

“This is not just a literature summary,” said Martin Kullen, vice president of human health, science, and innovation. “It’s a rigorous, peer-reviewed manuscript that validates the BB-12 strain’s mechanisms of action and clinical outcomes. And while this review brings together decades of research, it also opens the door for future discovery. As we continue to learn more about the microbiome and its role in human health, the BB-12 strain remains a cornerstone for innovation and exploration.”

When it comes to clinical efficacy, the review covers BB-12’s role in immune function, regular bowel movements, and colic. On a mechanistic level, it includes information on BB-12’s ability to survive the conditions of the gastrointestinal tract, and the strain’s transient colonization of epithelial and immune cells, which improves gut barrier function and modulates immune response. The review covers how the probiotic can enhance IgA secretion, modulate inflammation, and promote beneficial metabolic activity in the gut microbiome, such as increased short-chain fatty acid production.